STERIS Q2 adjusted EPS $2.14, revenue $1.3B (+7%); reiterates FY2025 outlook

STERIS plc

2025-Q2 EPS reported $2.98 vs consensus $2.29 ▲ beat (+30.4%)

Adjusted EPS from continuing operations $2.14 vs $1.86 prior year; as-reported EPS $1.51 vs $1.20.
Total revenue $1.3B, +7% as reported and constant currency organic growth.
Healthcare revenue +9% to $944.2M, driven by consumables (+12%) and service (+14%); capital equipment -2%.
AST revenue +9% to $256.7M; Life Sciences revenue -4% to $127.9M due to divestiture, organic +3%.
FY2025 outlook reiterated: revenue growth 6.5-7.5%, adjusted EPS $9.05-$9.25, free cash flow ~$700M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.